Spyre三款炎症性肠病抗体临床数据首次亮相欧洲胃肠病学周 联用增效临床前数据同步公布
Waltham——总部位于马萨诸塞州 Waltham 的临床阶段生物科技公司 Spyre Therapeutics（纳斯达克：SYRE）10月18日宣布，在 Barcelona 举行的2026年欧洲胃肠病学周（UEGW）上，首次在学术会议公布其三款炎症性肠病（IBD）抗体的临床数据：SPY001（抗α4β7）、SPY002（抗TL1A）与SPY003（抗IL-23）。三款药物正在 SKYLINE 研究中接受单药及两两联用测试，公司同时公布了显示联用增效的临床前数据。
口头报告于10月18日15时30分至15时40分（中欧夏令时）在 B3 会议室举行，题为「半衰期延长抗体 SPY001、SPY002 与 SPY003 诱导治疗中重度活动性溃疡性结肠炎的疗效与安全性」，报告人为米兰 San Raffaele Hospital 的 Silvio Danese 教授，他同时担任 SKYLINE 试验指导委员会主席。另一场海报报告定于10月19日16时06分在7号厅举行，报告三款抗体在人源化小鼠结肠炎模型中的疗效及联用进一步增效的结果，报告人为该公司 Andy Spencer。
Danese 表示，尽管炎症性肠病治疗已有显著进步，许多患者仍未达到或维持理想的疾病控制水平，这凸显了能带来更深、更持久应答的新疗法的需求；他认为先进联用疗法较当前单药疗法有很大概率增强疗效，Spyre 将针对已验证靶点的优化抗体组合起来，是该领域最有前景的管线之一，三款药物均已展示临床概念验证，团队期待明年的联用结果。
Spyre 是一家临床阶段生物科技公司，管线包括靶向α4β7、TL1A、IL-23 与 IL-17A/F 的长半衰期抗体及相应的合理联用项目。公司在公告中提示，相关表述含前瞻性陈述，实际结果可能与预期存在差异。
Spyre Presents First Clinical Data for All Three IBD Antibodies at UEGW 2026 in Barcelona
Waltham, Mass. — Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company based in Waltham, Massachusetts, announced on October 18 presentations at United European Gastroenterology Week (UEGW) 2026 in Barcelona, including the first scientific congress presentation of clinical data across all three of its IBD antibodies — SPY001 (anti-α4β7), SPY002 (anti-TL1A) and SPY003 (anti-IL-23) — which are being tested as monotherapies and pairwise combinations in the SKYLINE study, along with new preclinical data demonstrating additive efficacy of the complementary mechanisms.
The oral presentation, titled "Efficacy and Safety of Half-Life Extended Antibodies SPY001, SPY002, and SPY003 for Induction Treatment of Moderately to Severely Active Ulcerative Colitis," was scheduled for October 18, 3:30–3:40 p.m. CEST in Room B3, presented by Silvio Danese, M.D., Ph.D., of San Raffaele Hospital in Milan, who chairs the SKYLINE trial steering committee. A moderated poster on October 19 in Hall 7 presents data showing the three antibodies are efficacious in TNBS-induced colitis in humanized mice, with combinations further improving efficacy, presented by Andy Spencer, Ph.D., of Spyre.
Danese said that despite significant advances in IBD treatment, many patients still do not achieve or maintain the level of disease control clinicians would like to see, underscoring the need for new approaches that can deliver deeper and more durable responses. He said advanced combination therapy provides a strong probability of enhanced efficacy compared with today's monotherapies, and that with clinical proof-of-concept now demonstrated across SPY001, SPY002 and SPY003, the team is increasingly excited to see the combination results next year.
Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23 and IL-17A/F, as well as rational combination programs. The company noted that its announcement contains forward-looking statements and that actual results may differ.
发布：GSM·美国（发布链接）
图片来源：图：肠镜检查资料图，与本文所述炎症性肠病诊疗领域相关，非本次会议现场。图片来源：美国海军医学中心照片，公共领域，经 Wikimedia Commons。 Photo: A colonoscopy examination (file photo), related to the gastroenterology field covered in this report; not a scene from the congress. U.S. Navy photo, public domain, via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story
